CCT-217: A Landmark Gene Silencing Therapeutic for Weight Loss That Enhances Lean Mass Composition, Reduces Visceral, Subcutaneous Fat and Restores Metabolic Health in Obesity through Browning
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing Abstract According to the CDC, between 2017 and March 2020, 41.9% of U.S. adults aged 20 and older had obesity, with 9.2% experiencing severe obesity, affecting over 100 million and 22 million adults, respectively. Obesity prevalence increased from […]
